AWP
UTHR icon

Abacus Wealth Partners’s United Therapeutics UTHR Stock Holding History

Abacus Wealth Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$203K Sell
375
-47
-11% -$26.5K 0.02% 313
2026
Q1 		$250K Buy
422
+4
+1% +$1.99K 0.02% 413
2025
Q4 		$204K Buy
+418
New +$195K 0.02% 471

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Abacus Wealth Partners's UTHR Position: Q2 2026 in Review

Abacus Wealth Partners reduced its United Therapeutics (UTHR) stake by 11% in Q2 2026, selling an estimated $26.5K and leaving 375 shares worth $203K. The position accounts for 0.02% of the portfolio, ranked #313.

Abacus Wealth Partners first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $250K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Abacus Wealth Partners held 375 shares of United Therapeutics worth $203K as of Q2 2026.
  • Abacus Wealth Partners sold 47 United Therapeutics shares in Q2 2026, an estimated $26.5K.
  • United Therapeutics made up 0.02% of Abacus Wealth Partners's portfolio in Q2 2026, its #313 holding.
  • Abacus Wealth Partners first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Abacus Wealth Partners's United Therapeutics position peaked at $250K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Abacus Wealth Partners's 13F filing for Q2 2026, filed 22 Jul 2026.